Scientific Reports (Sep 2024)

Impact of ginsenoside Rb1 on gut microbiome and associated changes in pharmacokinetics in rats

  • Yue Chen,
  • Kang-xi Zhang,
  • Hui Liu,
  • Yue Zhu,
  • Qing-yun Bu,
  • Shu-xia Song,
  • Ya-chun Li,
  • Hong Zou,
  • Xiao-yan You,
  • Guo-ping Zhao

DOI
https://doi.org/10.1038/s41598-024-72225-1
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Ginsenoside Rb1 exhibits a wide range of biological activities, and gut microbiota is considered the main metabolic site for Rb1. However, the impact of gut microbiota on the pharmacokinetics of Rb1 are still uncertain. In this study, we investigated the gut microbiome changes and the pharmacokinetics after a 30 d Rb1 intervention. Results reveal that the systemic exposure and metabolic clearance rate of Rb1 and Rd were substantially affected after orally supplementing Rb1 (60 mg/kg) to rats. Significant increase in the relative abundance of Bacteroides cellulosilyticus in gut microbiota and specific glycoside hydrolase (GH) families, such as GH2, GH92, and GH20 were observed based on microbiome and metagenomic analysis. Moreover, a robust association was identified between the pharmacokinetic parameters of Rb1 and the relative abundance of specific Bacteroides species, and glycoside hydrolase families. Our study demonstrates that Rb1 administration significantly affects the gut microbiome, revealing a complex relationship between B. cellulosilyticus, key GH families, and Rb1 pharmacokinetics.

Keywords